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Abstract
The purpose of the present study was to evaluate the effects of bovine serum albumin (BSA) and
essentially fatty acid-free BSA (BSA-FAF) on the biliary clearance of compounds in sandwich-
cultured rat hepatocytes. Unbound fraction (fu), biliary excretion index (BEI), and unbound intrinsic
biliary clearance (intrinsic Cl’biliary) were determined for digoxin, pravastatin, and taurocholate in
the absence or presence of BSA or BSA-FAF. BSA had little effect on the BEI or intrinsic
Cl’biliary of these compounds. Surprisingly, BSA-FAF decreased both BEI and intrinsic Cl’biliary for
digoxin and pravastatin, which represent low and moderately-bound compounds, respectively. The
BEI and intrinsic Cl’biliary of taurocholate, a highly-bound compound, were not altered significantly
by BSA-FAF. Neither BSA nor BSA-FAF had a discernable effect on the bile canalicular networks,
based on carboxydichlorofluorescein (CDF) retention. The addition of physiological concentrations
of calcium, or the addition of fatty acids to BSA-FAF, was unable to restore the BEI or intrinsic
Cl’biliary of the model compounds to similar values in the absence or presence of BSA. Careful
consideration is warranted when selecting the type of BSA for addition to in vitro systems such as
sandwich-cultured rat hepatocytes.
INTRODUCTION
In vitro models are utilized widely to investigate hepatic metabolism and transport. Sandwich-
cultured rat hepatocytes are one such model system. Culturing primary hepatocytes between
two layers of extracellular matrix, which resembles basement membranes in vivo to which cells
attach, allows the cells to maintain many in vivo structural and functional characteristics. Apical
(canalicular) and basolateral (sinusoidal) membrane domains are re-established following
cellular repolarization and sealing of tight junction complexes, liver specific proteins are
expressed, and intact functional bile canalicular networks are formed (Hoffmaster et al.,
2004; LeCluyse et al., 1994; LeCluyse et al., 2000; Liu et al., 1998; Liu et al., 1999a). This
model has been established as an in vitro method to predict in vivo biliary clearance of drug
candidates (Fukuda et al., 2008; Liu et al., 1999b). It is a useful in vitro model to study hepatic
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uptake and biliary excretion mechanisms simultaneously. Data from medium, cell, and bile
compartments of sandwich-cultured hepatocytes can be used for pharmacokinetic modeling of
hepatobiliary drug disposition (Turncliff et al., 2006). Sandwich-cultured rat hepatocytes also
are used to predict drug and xenobiotic interactions that may occur in vivo at the level of hepatic
transporters (Annaert et al., 2005; Kemp et al., 2005; McRae et al., 2006).
Albumin and α1-acid glycoprotein are the primary proteins responsible for binding low-
molecular-weight compounds in plasma. As a general rule, cations bind to α1-acid
glycoprotein, while anions bind primarily to albumin (Peters, 1996). Albumin is the most
abundant protein present in plasma, and often is added to in vitro systems (Aungst et al.,
2000; Cross et al., 2003; Krishna et al., 2001; Neuhoff et al., 2006; Yamashita et al., 2000) to
prevent precipitation of water-insoluble drugs and to more closely mimic physiologic
conditions (Katneni et al., 2008). Bovine serum albumin (BSA) is utilized commonly in
vitro as a replacement for albumin from other species (Neuhoff et al., 2006; Saha and Kou,
2002; Taub et al., 2002).
A major determinant of drug disposition in vivo is binding to plasma proteins (Otagiri, 2005).
Many drug candidates are extensively protein-bound, tend to be hydrophobic and of limited
solubility, and are surface adsorptive, thus leading to experimental challenges in the drug
development process (Artursson, 1990; Wilson et al., 1990). The ability to deliver a compound
to, and stabilize a compound in, in vitro systems can be enhanced by the addition of protein.
However, such manipulation may significantly alter pharmacokinetic/pharmacodynamic
behavior (Bennhold, 1965; Fisher et al., 1999; Liu et al., 2005; Neuhoff et al., 2006; Wiseman
et al., 1964). Metabolic studies utilizing human liver microsomes, fresh or cryopreserved
hepatocytes, or transfected systems underpredict in vivo hepatic clearance and metabolic
inhibition potential (for review, see Rowland et al., 2007). Studies investigating the effect of
BSA on hepatic metabolism by UDP-glucuronosyltransferase (UGT) 2B7, UGT1A9, and
cytochrome P450 2C9 in these systems suggested an increase in in vitro intrinsic clearance in
the presence of BSA (for review, see Rowland et al., 2007; Rowland et al., 2008a, b). Similar
results were observed for UGT2B7 despite the preparation of BSA utilized [“crude”, essentially
fatty acid-free (BSA-FAF), essentially globulin-free, or essentially fatty acid-free and globulin-
free; Rowland et al., 2007]. It was hypothesized that BSA, despite the preparation type,
sequesters fatty acids that are inhibitory to the activity of metabolic enzymes (Rowland et al.,
2007); however, not all metabolic enzymes (UGT1A1; UGT1A6) are inhibited by fatty acids
(Rowland et al., 2008a).
Little work evaluating the effect of BSA on transport proteins and the hepatobiliary disposition
of compounds has been published. Previous investigations using transfected cells have focused
on transport proteins involved in the uptake of compounds into hepatocytes (Cui et al., 2001;
Hata et al., 2003; Shi et al., 1995). The primary objective of the present study was to
characterize the effect of BSA on the biliary excretion index (BEI) and biliary clearance of
compounds in sandwich-cultured rat hepatocytes. Because several preparations of albumin are
available commercially, we investigated the effects of BSA and BSA-FAF on these parameters.
The compounds selected for investigation (digoxin, pravastatin, and taurocholate) span a range
of unbound fractions: digoxin (fu~0.7; Lacy et al., 2002), pravastatin (fu~0.5; Hatanaka,
2000), and taurocholate (fu~0.15; Forker and Luxon, 1981; Hung et al., 2005). Additional
studies were designed to characterize: 1) the effect of albumin preparations on bile canalicular
networks, and 2) the effect of long chain fatty acids, which are present in BSA preparations,
on BEI and biliary clearance.
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Collagenase (type 1, class 1) was obtained from Worthington Biochemicals (Lakewood, NJ).
Dulbecco’s modified Eagle’s medium (DMEM, no phenol red), insulin, MEM non-essential
amino acids solution (100x), L-glutamine, penicillin G-streptomycin solution, and 5 (and 6)-
carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA) were purchased from Invitrogen
(Carlsbad, CA). Fetal bovine serum, sodium taurocholate, digoxin, Triton X-100,
dexamethasone, methanol, Hanks’ balanced salts solution (HBSS) modified with (H-1387) or
without (H-4891) calcium chloride, bovine serum albumin (BSA), essentially fatty acid-free
bovine serum albumin (BSA-FAF; A-8806), linoleic acid (18:2n-6), linolenic acid (18:3n-3),
oleic acid (18:1n-9), palmitic acid (16:0), palmitoleic acid (16:1n-7), and stearic acid (18:0)
were obtained from Sigma-Aldrich (St. Louis, MO). BioCoat™ collagen I plates, Matrigel™
basement membrane matrix, and ITS+™ (insulin/transferrin/selenium) culture supplement
were purchased from BD Biosciences Discovery Labware (Bedford, MA). Pravastatin and
d6-rosuvastatin were purchased from Toronto Research Chemicals (North York, Ontario,
Canada). [3H]-taurocholate (5 Ci/mmol, >97% purity) and [3H]-digoxin (40 Ci/mmol, >97%
purity) were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Bio-Safe
II™ liquid scintillation cocktail was obtained from Research Products International (Mt.
Prospect, IL). Centrifree® micropartition devices were obtained from Millipore (Billerica,
MA). Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein assay standard
were purchased from Pierce Chemical Co. (Rockford, IL). All other chemicals and reagents
were of analytical grade and available from commercial sources.
Animals
Male Wistar rats (200–325 g), obtained from Charles River Laboratories, Inc. (Raleigh, NC),
served as liver donors for hepatocyte isolation. Animals were maintained in a controlled
environment with a 12-h light/dark cycle and had free access to water and food prior to surgery.
All animal procedures were compliant with the guidelines of the University of North Carolina
at Chapel Hill Institutional Animal Care and Use Committee.
Isolation and In Vitro Culture of Primary Rat Hepatocytes
Hepatocytes were isolated from male Wistar rats using a two-step collagenase perfusion, as
described previously (LeCluyse et al., 1996). Cell viability, determined by trypan blue
exclusion, was >88%. Hepatocytes were seeded (~1.75 × 106 cells/well) in 6-well BioCoat™
plates in DMEM supplemented with 2 mM L-glutamine, 1% (v/v) MEM non-essential amino
acids, 100 units penicillin G sodium/mL, 100 μg streptomycin sulfate/mL, 1 μM
dexamethasone, 5% (v/v) fetal bovine serum, and 10 μM insulin (day 0 of culture), and cultured
in a humidified incubator (95% O2, 5% CO2) at 37°C. To achieve a sandwich configuration
24 h post-plating (day 1 of culture), hepatocytes were overlaid with Matrigel™ basement
membrane matrix (0.25 mg/mL) in 2 mL/well cold serum-free DMEM containing 2 mM L-
glutamine, 1% (v/v) MEM non-essential amino acids, 100 units penicillin G sodium/mL, 100
μg streptomycin sulfate/mL, 0.1 μM dexamethasone, and 1% (v/v) ITS+™. The culture medium
was changed every 24 h until experiments were performed on day 4 of culture.
Accumulation Experiments
The method to determine substrate accumulation in sandwich-cultured rat hepatocytes has been
described previously (Liu et al., 1999a). Briefly, hepatocytes were rinsed twice with 2 mL
warm HBSS containing Ca2+ (standard buffer) or Ca2+-free HBSS and incubated with 2 mL
of the same buffer for 10 min at 37°C (to maintain tight junction integrity and bile canalicular
networks or disrupt tight junctions and open bile canalicular networks, respectively). The buffer
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was removed, and the cells were incubated for 10 min at 37°C with 1.5 mL of [3H]-taurocholate
(1 μM), [3H]-digoxin (10 μM), or pravastatin (5 μM) in standard buffer in the presence or
absence of 4% (w/v) BSA or BSA-FAF. For experiments in which long chain fatty acids were
added, standard buffer with or without BSA or BSA-FAF remained at room temperature for
~1 h following the addition of long chain fatty acids (diluted in dimethyl sulfoxide) to allow
binding of the fatty acids to albumin (Peters, 1996) prior to the addition of pravastatin and
subsequent incubation with hepatocytes for 10 min. The fatty acids added were linoleic acid
(5.48 μM), linolenic acid (0.20 μM), oleic acid (6.94 μM), palmitic acid (9.38 μM), palmitoleic
acid (0.76 μM), and stearic acid (7 μM). Hepatocytes were rinsed vigorously three times with
2 mL ice-cold standard buffer following the incubation. For rinsing of [3H]-digoxin-treated
hepatocytes, 10 μM unlabeled digoxin was added to the rinsing buffer to reduce nonspecific
binding as described previously (Annaert et al., 2001). Additional digoxin accumulation
studies were performed with or without 1 mM Ca2+ (calcium chloride) added to the digoxin-
containing incubation solution. Taurocholate- and digoxin-treated hepatocytes were lysed with
1 mL 0.5% (v/v) Triton X-100 in phosphate-buffered saline by placing plates on an orbital
shaker for a minimum of 20 min at room temperature. The samples were analyzed by liquid
scintillation spectroscopy in a Packard Tri-Carb scintillation counter (PerkinElmer Life and
Analytical Sciences). Pravastatin-treated hepatocytes were lysed with 1 mL 70% (v/v) ice-cold
methanol/water, scraped off the plates, and sonicated for 20 sec with a sonic dismembrator.
The samples were analyzed by liquid chromatography with detection by tandem mass
spectrometry (LC/MS/MS).
LC/MS/MS Analysis
Hepatocyte lysates from pravastatin accumulation experiments were centrifuged at 12,000g
for 5 min at 4°C. The resulting supernatants were diluted 1:6 with water and methanol
containing the internal standard (d6-rosuvastatin). Analysis of these samples was performed
with a Shimadzu solvent delivery system (Shimadzu Scientific Instruments, Columbia, MD)
and a Leap HTC Pal thermostated autosampler (LEAP Technologies, Carrboro, NC) connected
to an Applied Biosystems API 4000 triple quadrupole mass spectrometer with a TurboSpray
ion source (Applied Biosystems, Foster City, CA). Tuning, operation, integration, and data
analysis were performed in positive mode using multiple reaction monitoring (Analyst software
v.1.4.1; Applied Biosystems). Ten microliters of sample were injected onto an Aquasil 5-μM
C18 column (2.1 mm i.d. × 50 mm; Thermo Electron Corporation, Waltham, MA). The mobile
phase consisted of 0.1% (v/v) formic acid diluted in water (Buffer A) and methanol containing
0.1% (v/v) formic acid (Buffer B). Analytes were eluted with a high-pressure linear gradient
program at a flow rate of 0.75 mL/min as follows: 20% buffer B for 0.75 min, increased to
40% buffer B over 0.64 min and held for 1.91 min, rapidly increased to 90% buffer B and held
for 0.7 min, and returned rapidly to 20% buffer B. The system was allowed to re-equilibrate
for 1 min, with a total run time of 5 min per injection. The entire column effluent was diverted
from the TurboSpray ion probe of the mass spectrometer for the first 0.75 min and last 1 min.
An eight point calibration curve (2–1000 nM) was constructed for pravastatin using peak area
ratios of analyte and internal standard using the following transitions: pravastatin (447.1 →
327.4) and d6-rosuvastatin (488.2 → 264.2). All points on the curve back-calculated to within
±15% of the nominal value.
Nonspecific Binding and Protein Determination
All accumulation data were corrected for nonspecific binding of the relevant substrate to
Matrigel™-overlaid hepatocyte-free BioCoat™ plates. The data also were normalized to the
protein concentration in each well (lysed with Triton X-100), determined in duplicate aliquots
using BCA protein assay reagents as instructed by the manufacturer. BSA, as supplied by the
manufacturer, was used as a standard (0.2 – 1 mg/mL). Due to the incompatibility of methanol
with the BCA protein assay, the average protein concentration of samples from one liver
Wolf et al. Page 4













preparation lysed with Triton X-100 was used to normalize the accumulation data of samples
lysed with methanol from the same liver preparation.
Determination of Protein Binding
The unbound fraction (fu) of each compound was determined over a range of concentrations:
taurocholate (0.1–100 μM), digoxin (0.1–30 μM), and pravastatin (1–10 μM). This
determination was not performed to examine the binding kinetics of each compound, but rather
to ensure that binding was stable and reproducible under the conditions planned for the
experiment. Solutions in standard buffer were prepared in the absence or presence of 4% (w/
v) BSA or BSA-FAF and incubated at 37°C for 30 min. Solutions containing long chain fatty
acids were prepared in a manner similar to that described under Accumulation Experiments,
prior to the addition of pravastatin and incubation for 30 min at 37°C. Media samples from
sandwich-cultured rat hepatocyte experiments also were taken to determine the fu of digoxin.
Samples (1 mL) were placed in Centrifree® micropartition devices and centrifuged at 1500g
at 37°C for either 30 sec (non-BSA-containing samples) or 4 min (BSA-containing samples)
to pass ~10% of the original volume through the filter. The absence-of-protein condition was
used to assess non-specific binding. Samples were obtained from above (total concentration
in the presence of protein) and below (unbound concentration) the filter. Substrate
concentrations, determined by either liquid scintillation spectroscopy (taurocholate and
digoxin) or LC/MS/MS (pravastatin), were used to calculate fu. The fu of digoxin in the absence
or presence of BSA or BSA-FAF in the cell-free system was similar to the fu in sandwich-
cultured rat hepatocyte experiments (results not shown); therefore, the fu of pravastatin and
taurocholate were not determined in sandwich-cultured rat hepatocytes.
Fluorescence Microscopy
Retention of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) in bile canalicular networks
in the absence or presence of BSA or BSA-FAF was examined. Hepatocytes were rinsed twice
with 2 mL standard buffer and incubated with 2 mL of the same buffer at 37°C for 10 min.
The buffer was removed, and the cells were incubated for 10 min at 37°C with 1.5 mL CDFDA
(2 μM) in standard buffer to preload the bile canaliculi with CDF. Subsequently, hepatocytes
were incubated with standard buffer in the absence or presence of 4% (w/v) BSA or BSA-FAF
for 10 min, during which time the cells and bile canaliculi were imaged with a Zeiss Axiovert
100TV inverted fluorescent microscope (Carl Zeiss Inc., Thornwood, NY).
Data Analysis
The BEI (%) and unbound intrinsic biliary clearance (intrinsic Cl’biliary, mL/min/kg) were
calculated using B-CLEAR® technology (Qualyst, Inc., Raleigh, NC; Liu et al., 1999a):
(1)
where substrate accumulation in the cell + bile compartments was determined in hepatocytes
preincubated in standard buffer; cellular accumulation of substrate was determined in
hepatocytes preincubated with Ca2+-free HBSS.
(2)
where fu represents the unbound fraction of substrate (fu = 1 in the case of no BSA) and
AUCmedia represents the area under the substrate concentration-time curve, determined by
dividing the sum of the substrate concentration in the incubation medium at the beginning and
end of the incubation period by 2, and multiplying by the incubation time (10 min). Intrinsic
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Cl’biliary values were converted to mL/min/kg based on 200 mg protein/g of liver and 40 g
liver/kg of rat body weight (Seglen, 1976).
Statistical Analysis
Data are represented as mean and the associated S.E.M., S.D., or range, as appropriate.
Statistical comparisons were performed with SigmaStat (SPSS Inc., Chicago, IL). The effects
of BSA and BSA-FAF, at a single concentration of compound and a single concentration of
BSA, on BEI and intrinsic Cl’biliary were evaluated by one-way analysis of variance (ANOVA)
with Tukey’s post-hoc test in order to determine whether the presence and type of BSA affected
either of these parameters. The effects on fu were evaluated by two-way ANOVA with Tukey’s
post-hoc test, using log transformed data when appropriate for statistical comparisons, in order
to determine whether the fu of each compound was significantly altered by the type of BSA
utilized or by the concentration of compound. In all cases, p < 0.05 was considered statistically
significant.
RESULTS
Effect of BSA and BSA-FAF on Digoxin Hepatobiliary Disposition
Figure 1 shows the effect of BSA and BSA-FAF on the fu, BEI and intrinsic Cl’biliary of digoxin.
The fu, determined by ultrafiltration, was concentration-independent from 0.1–30 μM (results
not shown), but was significantly higher in the presence of BSA compared to BSA-FAF (p <
0.05). Digoxin binding to albumin was minimal: 18% in the presence of BSA and 33% in the
presence of BSA-FAF. The BEI and intrinsic Cl’biliary of digoxin were not altered by the
presence or absence of BSA. However, BSA-FAF significantly decreased both BEI and
intrinsic Cl’biliary compared to no BSA or BSA conditions (p < 0.05).
Effect of BSA and BSA-FAF on Pravastatin Hepatobiliary Disposition
The effects of BSA and BSA-FAF on pravastatin fu, BEI, and intrinsic Cl’biliary are illustrated
in Figure 2. The fu was concentration-independent from 1–10 μM (results not shown), but was
significantly higher in the presence of BSA compared to BSA-FAF (p < 0.05). Pravastatin was
moderately-bound to albumin: 39% in the presence of BSA and 50% in the presence of BSA-
FAF. The intrinsic Cl’biliary of pravastatin was not significantly different in the presence or
absence of BSA. However, BSA-FAF significantly decreased both BEI and intrinsic
Cl’biliary of pravastatin compared to values in the absence or presence of BSA (p < 0.05).
Effect of BSA and BSA-FAF on Taurocholate Hepatobiliary Disposition
Figure 3 shows the effect of BSA and BSA-FAF on the fu, BEI, and intrinsic Cl’biliary of
taurocholate. The fu was concentration-independent from 0.1–100 μM (results not shown), but
was significantly higher in the presence of BSA compared to BSA-FAF (p < 0.05). Despite
the fact that taurocholate was highly bound to albumin (approximately 85% in the presence of
BSA or BSA-FAF), the BEI and intrinsic Cl’biliary of taurocholate were unaffected by BSA.
Effect of BSA and BSA-FAF on CDF Retention in Bile Canaliculi
CDFDA readily diffuses into hepatocytes, where it is hydrolyzed rapidly to CDF and excreted
into the bile canaliculi by multidrug resistance-associated protein (Mrp) 2. After pre-incubating
hepatocytes for 10 min with CDFDA, CDF retention was evaluated over 10 min in the absence
or presence of BSA or BSA-FAF to assess the maintenance of tight junction integrity (Figure
4). BSA and BSA-FAF had no discernable effects on CDF accumulation in bile canalicular
networks over the 10-min period compared to the no BSA condition.
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Effect of Additional Ca2+ on the Hepatobiliary Disposition of Digoxin in the Absence or
Presence of BSA or BSA-FAF
Figure 5 shows the effect of BSA and BSA-FAF on the BEI and intrinsic Cl’biliary of digoxin
in the presence of additional Ca2+. Similar to the results in Figure 1, the BEI and intrinsic
Cl’biliary of digoxin were not affected by BSA compared to no BSA, while BSA-FAF decreased
both parameters. The addition of 1 mM Ca2+ was unable to restore digoxin BEI and intrinsic
Cl’biliary values in the presence of BSA-FAF to similar values in the presence or absence of
BSA. Similar findings were obtained with the addition of 2.5 mM Ca2+ (results not shown).
Effect of the Addition of Fatty Acids to BSA or BSA-FAF on Pravastatin Hepatobiliary
Disposition
Rowland et al. (2007) reported that palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1n-9),
linoleic acid (18:2n-6), palmitoleic acid (16:1n-7), and linolenic acid (18:3n-3) are six of the
predominant long chain fatty acids present in BSA. To determine whether addition of these
fatty acids to BSA-FAF restored the BEI and intrinsic Cl’biliary of pravastatin, additional
experiments were conducted (Figure 6. As described previously (Figure 2), the fu was
significantly higher in the presence of BSA compared to BSA-FAF (p < 0.05). The BEI and
intrinsic Cl’biliary of pravastatin in the presence of BSA were similar to values in the absence
of BSA with or without the addition of fatty acids. BSA-FAF decreased the fu, BEI, and intrinsic
Cl’biliary of pravastatin compared to the absence or presence of BSA, and the addition of fatty
acids to BSA-FAF was unable to mitigate this effect.
DISCUSSION
Protein often is added to in vitro systems to facilitate delivery and improve the stability of drug
candidates, to prevent precipitation of water-insoluble compounds, and to minimize adsorption
to experimental apparatuses (Artursson, 1990; Katneni et al., 2008; Saha and Kou, 2002;
Wilson et al., 1990). Albumin is the most abundant plasma protein, and therefore is added most
frequently, typically in the form of BSA (Aungst et al., 2000; Cross et al., 2003; Krishna et
al., 2001; Neuhoff et al., 2006; Yamashita et al., 2000). Different BSA preparations are
commercially available and BSA-FAF is used frequently for in vitro experiments. The effects
of different types of BSA on biliary clearance estimates in sandwich-cultured hepatocytes have
not been reported to date. This study evaluated the effect of BSA and BSA-FAF on BEI and
biliary clearance in sandwich-cultured rat hepatocytes for three compounds representing
different degrees of protein binding: digoxin (low binding); pravastatin (moderate binding);
and taurocholate (high binding).
The equilibrium unbound fraction of a compound is an important determinant of hepatic
uptake; it is assumed that only the unbound species is available to traverse the hepatic
basolateral membrane. While this is a common assumption, it might not be true in all cases.
For example, if protein binding of a particular compound is labile, such that the rate constants
governing binding onset and offset are rapid, uptake may appear to occur for both the bound
and unbound pool if the uptake process is very efficient (i.e., if the compound could be classified
as a “high extraction” substrate). The fu must be taken into account when calculating the
intrinsic Cl’biliary (Equation 2) of digoxin, pravastatin, and taurocholate. As expected, the fu
of each compound was significantly decreased in the presence, compared to the absence, of
BSA (Figures 1–3). Our data consistently show that intrinsic Cl’biliary, when corrected for fu,
is similar in the absence or presence of BSA (Figures 1–3). In addition, the BEI of digoxin and
taurocholate showed comparable results in the absence and presence of BSA. Similar to the
present observations, Liu et al. (2005) reported no difference in digoxin clearance between
isolated rat livers perfused with Krebs-Henseleit bicarbonate (KHB) buffer alone or KHB
buffer containing BSA and red blood cells, after correcting for the fu of digoxin. These results
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confirm the importance of accounting for the fu of a compound when calculating intrinsic
Cl’biliary.
Surprisingly, the intrinsic Cl’biliary of digoxin and pravastatin in the presence of BSA-FAF was
significantly decreased compared to values determined in the presence or absence of BSA when
fu was taken into account (Figures 1–2); comparable differences were observed for the BEI.
The fu of each compound also was significantly lower in the presence of BSA-FAF (Figures
1–2). Fatty acids may either compete for binding sites on albumin, produce electrostatic effects
that influence the binding of compounds to albumin, or bind to albumin and produce
conformational changes that affect the binding of other compounds (Bertucci and Domenici,
2002; Kragh-Hansen et al., 2002; Otagiri, 2005). The type of effect that occurs may be
substrate-dependent. In this in vitro system, BSA-FAF decreased the fu of digoxin, pravastatin,
and taurocholate (Figures 1–3). Despite the difference in fu in the presence of BSA-FAF, the
increased binding of digoxin and pravastatin to BSA-FAF did not account for the differences
observed in BEI and intrinsic Cl’biliary for these compounds.
Addition of BSA to incubations of HeLa cells stably transfected with rat sodium-taurocholate
co-transporting polypeptide (Ntcp) or organic anion-transporting polypeptide (Oatp) 1
(Oatp1a1) decreased the uptake of [35S]-sulfobromophthalein (Hata et al., 2003; Shi et al.,
1995). Similarly, Cui et al. (2001) reported that addition of human serum albumin to HEK293
cells stably expressing recombinant human OATP2 (OATP1B1) or OATP8 (OATP1B3)
abolished OATP8-mediated [3H]-sulfobromophthalein uptake, but did not significantly affect
OATP2-mediated [3H]-sulfobromophthalein uptake. These findings suggest that decreased
substrate accumulation may depend on whether albumin inhibits the transport protein(s)
involved in the uptake of a particular substrate, as well as on the relative contribution of each
transport protein to uptake. The hepatic uptake of digoxin and pravastatin is Oatp-mediated
(Hsiang et al., 1999; Noé et al., 1997; Sasaki et al., 2004; Shitara et al., 2002; Tokui et al.,
1999). Although taurocholate is a substrate for multiple Oatps, Ntcp is the primary transport
protein responsible for hepatic uptake of taurocholate in rat hepatocytes (Oude Elferink et
al., 1995). In the present study, the accumulation of taurocholate was notably decreased in the
presence of BSA or BSA-FAF (Figure 3). The present findings are consistent with the
hypothesis that BSA and BSA-FAF inhibit Ntcp-mediated transport in sandwich-cultured rat
hepatocytes. Based on these data, a decrease in the intrinsic Cl’biliary of taurocholate was
expected. The observation that BSA-FAF significantly decreased BEI and intrinsic Cl’biliary
values for digoxin and pravastatin, but not taurocholate, further emphasizes the complexity of
the albumin effect, and suggests that the findings cannot be explained simply by direct
inhibition of specific transport proteins.
One possible mechanism by which BSA-FAF might affect BEI and intrinsic Cl’biliary in
sandwich-cultured rat hepatocytes involves alterations in the maintenance of tight junction
integrity. To investigate this possibility, CDF retention in sandwich-cultured rat hepatocytes
in the absence or presence of BSA and BSA-FAF was studied over a 10-min period (Figure
4). CDFDA is hydrolyzed to CDF within hepatocytes and is transported into the bile canalicular
networks by Mrp2. CDF accumulates in these networks if the integrity of the tight junction
complexes have not been compromised by the absence of Ca2+ (Liu et al., 1999a), or some
other factor. No obvious differences were observed in CDF retention in bile canalicular
networks in the presence of BSA or BSA-FAF compared to accumulation in networks in the
absence of BSA. These results suggest that the bile canalicular networks remain sealed in the
presence of BSA and BSA-FAF, and that the proteins comprising the tight junctions are not
modulated.
Preparation of BSA-FAF involves the incubation of BSA with activated charcoal. In addition
to removal of fatty acids, other components may be removed, including calcium and other ions.
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Thus, BSA-FAF may have increased potential to bind calcium. Therefore, we evaluated the
addition of physiological concentrations of calcium. Additional 1 mM Ca2+ (Figure 5), or 2.5
mM Ca2+ (data not shown), did not mitigate the effect of BSA-FAF on the BEI or intrinsic
Cl’biliary of digoxin, suggesting that the mechanism of the BSA-FAF effect is not through the
modulation of Ca2+ levels. It is unlikely that a contaminant in the BSA-FAF preparation is
chelating Ca2+ and preventing the maintenance of tight junction integrity and formation of
sealed bile canalicular networks.
Fatty acids have been reported to inhibit the activity of some metabolic enzymes (Rowland et
al., 2007; Rowland et al., 2008a, b), and any BSA preparation can protect against this by
sequestering the inhibitory fatty acids (Rowland et al., 2007). Therefore, we evaluated whether
the addition of six of the predominant long chain fatty acids present in BSA [linoleic acid,
linolenic acid, oleic acid, palmitic acid, palmitoleic acid and stearic acid (Rowland et al.,
2007)], would mitigate the decrease in the BEI and intrinsic Cl’biliary of pravastatin observed
in the presence of BSA-FAF compared to values in the presence or absence of BSA. Addition
of fatty acids did not modulate the effect of BSA-FAF on the BEI and intrinsic Cl’biliary of
pravastatin (Figure 6). Further work is required to elucidate the mechanism(s) responsible for
the decreased BEI and intrinsic Cl’biliary values observed in the presence of BSA-FAF.
In conclusion, the results of this study indicate that the type of BSA that is added to sandwich-
cultured rat hepatocytes can affect the BEI and predicted in vivo biliary clearance values.
Addition of BSA yielded results consistent with the BEI and intrinsic Cl’biliary determined in
the absence of BSA. In contrast, BSA-FAF significantly decreased the BEI and intrinsic
Cl’biliary of some substrates. The selection of proteins for addition to in vitro systems requires
careful consideration. The present observations suggest that, when necessary, BSA rather than
BSA-FAF should be added in vitro to sandwich-cultured rat hepatocytes for determination of
BEI and biliary clearance values.
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Figure 1. Hepatobiliary disposition of digoxin in the absence or presence of BSA or BSA-FAF
Sandwich-cultured rat hepatocytes were incubated with [3H]-digoxin (10 μM) in the absence
or presence of 4% (w/v) bovine serum albumin (BSA) or essentially fatty acid-free BSA (BSA-
FAF) for 10 min following incubation in standard or Ca2+-free buffer. Filled bars represent
accumulation in hepatocytes and bile canaliculi (cell + bile). Open bars represent accumulation
in hepatocytes (cell). The biliary excretion index (BEI), unbound intrinsic biliary clearance
(intrinsic Cl’biliary), and unbound fraction (fu) were determined as described under Methods.
Data are presented as mean ± S.E.M. n = 3 livers in triplicate. Groups with the same letter
indicate a statistically significant difference (p < 0.05).
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Figure 2. Hepatobiliary disposition of pravastatin in the absence or presence of BSA or BSA-FAF
Sandwich-cultured rat hepatocytes were incubated with pravastatin (5 μM) in the absence or
presence of 4% (w/v) BSA or BSA-FAF for 10 min following incubation in standard or
Ca2+-free buffer. Filled bars represent accumulation in hepatocytes and bile canaliculi (cell +
bile). Open bars represent accumulation in hepatocytes (cell). BEI, intrinsic Cl’biliary, and fu
were determined as described under Methods. Data are presented as mean ± S.E.M. n = 3 livers
in triplicate. Groups with the same letter indicate a statistically significant difference (p < 0.05).
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Figure 3. Hepatobiliary disposition of taurocholate in the absence or presence of BSA or BSA-FAF
Sandwich-cultured rat hepatocytes were incubated with [3H]-taurocholate (1 μM) in the
absence or presence of 4% (w/v) BSA or BSA-FAF for 10 min following incubation in standard
or Ca2+-free buffer. Filled bars represent accumulation in hepatocytes and bile canaliculi (cell
+ bile). Open bars represent accumulation in hepatocytes (cell). BEI, intrinsic Cl’biliary, and
fu were determined as described under Methods. Data are presented as mean ± S.E.M. n = 3
livers in triplicate. The taurocholate fu data were log-transformed for statistical comparison.
Groups with the same letter indicate a statistically significant difference (p < 0.05).
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Figure 4. Retention of carboxydichlorofluorescein (CDF) in bile canaliculi in the absence or
presence of BSA or BSA-FAF
Sandwich-cultured rat hepatocytes were incubated with carboxydichlorofluorescein diacetate
(CDFDA; 2 μM) in standard buffer for 10 min to preload the bile canaliculi with CDF.
Subsequently, hepatocytes were imaged for 10 min in the absence or presence of BSA or BSA-
FAF. Representative images of CDF fluorescence during the 10 min period are shown.
Wolf et al. Page 16













Figure 5. Effect of additional Ca2+ on the hepatobiliary disposition of digoxin in the absence or
presence of BSA or BSA-FAF
Sandwich-cultured rat hepatocytes were incubated with [3H]-digoxin (10 μM) in the absence
or presence of 4% (w/v) BSA or BSA-FAF with or without 1 mM Ca2+ (calcium chloride) for
10 min following incubation in standard or Ca2+-free buffer. Filled bars represent accumulation
in hepatocytes and bile canaliculi (cell + bile). Open bars represent accumulation in hepatocytes
(cell). The BEI and intrinsic Cl’biliary were determined as described under Methods. Data are
presented as mean ± range. n = 1 liver in duplicate.
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Figure 6. Effect of the addition of fatty acids to BSA-FAF on pravastatin hepatobiliary disposition
Sandwich-cultured rat hepatocytes were incubated with pravastatin (5 μM) in the absence or
presence of 4% (w/v) BSA or BSA-FAF, with or without addition of long chain fatty acids or
vehicle (dimethyl sulfoxide; DMSO), for 10 min following incubation in standard or Ca2+-free
buffer. Long chain fatty acids [linoleic acid (5.48 μM), linolenic acid (0.20 μM), oleic acid
(6.94 μM), palmitic acid (9.38 μM), palmitoleic acid (0.76 μM), and stearic acid (7 μM)] were
added to standard buffer with or without BSA-FAF and preincubated at room temperature for
~1 h prior to the addition of pravastatin. Filled bars represent accumulation in hepatocytes and
bile canaliculi (cell + bile). Open bars represent accumulation in hepatocytes (cell). BEI,
intrinsic Cl’biliary, and fu were determined as described under Methods. Data are presented as
mean ± S.E.M. n = 1 liver in triplicate.
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